5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry

Following successful phase-III trials, direct oral anticoagulants such as rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF). However, data from randomized trials should be confirmed in unselected cohorts.

Source: Thrombosis Research - March 7, 2021 Category: Hematology Authors: Luise Tittl, Sandra Marten, Christiane Naue, Jan Beyer-Westendorf Tags: Full Length Article Source Type: research